Study treatment for hepatitis C that did not work before
Part of Digestive system, Infections clinical trials.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent (paper consent or fingerprint).
- You must live in the local study area and plan to stay there during the study.
- You have confirmed active hepatitis C infection (a positive hepatitis C lab test like HCV RNA or core antigen).
- You had government-recommended hepatitis C treatment in the past 24 months, but it did not work well enough (so-called treatment failure).
- You must have a recent test showing whether you have liver scarring/cirrhosis (using FibroScan, blood-based score, or a liver biopsy).
- You can provide a stored blood sample or agree to give a blood sample, plus you can do required scans/tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
This study tests a pill combination (sofosbuvir/velpatasvir) to cure hepatitis C. It aims to make treatment simple and accessible, and you can join even if you've had treatment before (if it failed or you got reinfected).
This trial compares a simplified way of testing and treating hepatitis C with the standard approach. It aims to see if the simpler method works just as well and makes it easier for people to get treated.
This study offers a once-daily pill (Epclusa) to treat hepatitis C for people in jail who have never taken HCV medicine before. The goal is to see if starting treatment while incarcerated and continuing after release can cure the infection.
Hear when a new Hepatitis C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.